Search Results - "Wamil, Barbara"
-
1
CM101-Mediated Recovery of Walking Ability in Adult Mice Paralyzed by Spinal Cord Injury
Published in Proceedings of the National Academy of Sciences - PNAS (27-10-1998)“…CM101, an antiangiogenic polysaccharide derived from group B streptococcus, was administered by i.v. injection 1 hr post-spinal-cord crush injury in an effort…”
Get full text
Journal Article -
2
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
Published in Journal of clinical oncology (01-04-2017)“…Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in…”
Get full text
Journal Article -
3
Macrophage stimulation using a group B-streptococcus exotoxin (CM101) leads to axonal regrowth in the injured optic nerve
Published in Restorative neurology and neuroscience (2004)“…A group B-streptococcus exotoxin (CM101) was administered following optic nerve injury in adult rats in order to analyze putative effects on macrophages, glial…”
Get more information
Journal Article -
4
Identification of a Novel Membrane Protein, HP59, with Therapeutic Potential as a Target of Tumor Angiogenesis
Published in Clinical cancer research (01-12-2001)“…CM101, a polysaccharide isolated from the culture medium of Group B streptococcus, a neonatal pathogen, targets pathological angiogenesis and inhibits tumor…”
Get full text
Journal Article -
5
An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10)
Published in Journal of clinical oncology (20-05-2020)“…Abstract only 3520 Background: Prior studies have confirmed the efficacy and safety of ceritinib in patients (pts) with advanced ALK+ non-small cell lung…”
Get full text
Journal Article -
6
CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis
Published in Cancer research (Chicago, Ill.) (15-10-2000)“…CM101, a bacterial polysaccharide exotoxin produced by group B Streptococcus (GBS), also referred to as GBS toxin, has been shown to target pathological…”
Get full text
Journal Article -
7
CM101 stimulates cutaneous wound healing through an anti-angiogenic mechanism
Published in Angiogenesis (London) (2001)“…CM101, an anti-pathoangiogenic polysaccharide derived from group B streptococcus, has been shown to inhibit inflammatory angiogenesis and accelerate wound…”
Get full text
Journal Article -
8
Isolation and identification of the group B streptococcal toxin CM101 from infants with sepsis
Published in The Journal of pediatrics (01-09-2000)“…Objective: To determine whether the group B streptococcal (GBS) polysaccharide exotoxin CM101, which induces a complement-activated cytokine-driven…”
Get full text
Journal Article -
9
TOPIC: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients with First Clinical Episode Consistent With Multiple Sclerosis (PL2.002)
Published in Neurology (08-04-2014)“…Abstract only…”
Get full text
Journal Article -
10
Functional studies on the anti-pathoangiogenic properties of CM101
Published in Angiogenesis (London) (1998)“…Group B streptococcus (GBS) isolated from human neonates diagnosed with sepsis and respiratory distress produces a polysaccharide exotoxin (CM101) which has…”
Get full text
Journal Article -
11
Phase I study of the antineovascularization drug CM101
Published in Clinical cancer research (01-03-1997)“…CM101 is a bacterial polysaccharide that induces neovascular inflammation in malignant tumors. Fifteen patients with refractory malignancies received CM101…”
Get full text
Journal Article -
12
-
13
ISOLATION AND IDENTIFICATION OF GROUP B β-HEMOLYTIC STREPTOCOCCAL (GBS) TOXIN FROM SEPTIC NEWBORN INFANTS. • 1796
Published in Pediatric research (01-04-1996)Get full text
Journal Article -
14
Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial
Published in Journal of cancer research and clinical oncology (01-03-1997)“…A polysaccharide toxin, GBS toxin, is produced by group BStreptococcus (GBS) isolates from neonates who died of "early-onset disease". GBS toxin, named CM101…”
Get full text
Journal Article